Home >> Research Area >>Others>>Guanylyl Cyclase>> CFM 1571 hydrochloride

CFM 1571 hydrochloride

sGC activator CAS# 1215548-30-3

CFM 1571 hydrochloride

Catalog No. BCC5924----Order now to get a substantial discount!

Product Name & Size Price Stock
CFM 1571 hydrochloride: 5mg $127 In Stock
CFM 1571 hydrochloride: 10mg Please Inquire In Stock
CFM 1571 hydrochloride: 20mg Please Inquire Please Inquire
CFM 1571 hydrochloride: 50mg Please Inquire Please Inquire
CFM 1571 hydrochloride: 100mg Please Inquire Please Inquire
CFM 1571 hydrochloride: 200mg Please Inquire Please Inquire
CFM 1571 hydrochloride: 500mg Please Inquire Please Inquire
CFM 1571 hydrochloride: 1000mg Please Inquire Please Inquire
Related Products

Quality Control of CFM 1571 hydrochloride

Number of papers citing our products

Chemical structure

CFM 1571 hydrochloride

3D structure

Chemical Properties of CFM 1571 hydrochloride

Cas No. 1215548-30-3 SDF Download SDF
PubChem ID 56972190 Appearance Powder
Formula C23H29ClN4O3 M.Wt 444.95
Type of Compound N/A Storage Desiccate at -20°C
Solubility Soluble to 100 mM in water and to 100 mM in DMSO
Chemical Name 2-benzyl-5-[3-(dimethylamino)propoxy]-N-(4-methoxyphenyl)pyrazole-3-carboxamide;hydrochloride
SMILES CN(C)CCCOC1=NN(C(=C1)C(=O)NC2=CC=C(C=C2)OC)CC3=CC=CC=C3.Cl
Standard InChIKey DFVHCFCSCUCAPD-UHFFFAOYSA-N
Standard InChI InChI=1S/C23H28N4O3.ClH/c1-26(2)14-7-15-30-22-16-21(27(25-22)17-18-8-5-4-6-9-18)23(28)24-19-10-12-20(29-3)13-11-19;/h4-6,8-13,16H,7,14-15,17H2,1-3H3,(H,24,28);1H
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Biological Activity of CFM 1571 hydrochloride

DescriptionSoluble guanylyl cyclase (sGC) activator (EC50 = 5.49 μM). Does not activate adenylyl cyclase, shows no significant inhibition of phosphodiesterases and displays minimal inhibition of iNOS (25%) and nNOS (17%). Inhibits collagen-stimulated platelet aggregation in vitro (IC50 = 2.84 μM).

CFM 1571 hydrochloride Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

CFM 1571 hydrochloride Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of CFM 1571 hydrochloride

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 2.2474 mL 11.2372 mL 22.4744 mL 44.9489 mL 56.1861 mL
5 mM 0.4495 mL 2.2474 mL 4.4949 mL 8.9898 mL 11.2372 mL
10 mM 0.2247 mL 1.1237 mL 2.2474 mL 4.4949 mL 5.6186 mL
50 mM 0.0449 mL 0.2247 mL 0.4495 mL 0.899 mL 1.1237 mL
100 mM 0.0225 mL 0.1124 mL 0.2247 mL 0.4495 mL 0.5619 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University

Background on CFM 1571 hydrochloride

IC50: 2.84 μM for platelet

Soluble guanylate cyclase (sGC) is a key signal-transduction enzyme activated by nitric oxide (NO). Impaired bioavailability and/or responsiveness to endogenous NO has been implicated in the pathogenesis of cardiovascular and other diseases. CFM 1571 is a activator of the nitric oxide receptor, soluble guanylate cyclase.

In vitro: CFM 1571 demonstrated potent activation of soluble guanylate cyclase and potent inhibition of platelet aggregation. CFM 1571 also showed enzyme activity similar to benzydamine. CFM 1571 was additionally assayed against the NOS isoforms, and minimal inhibition was observed with iNOS (25%) and nNOS (17%). Furthermore CFM 1571 shows no significant activity at any of the other enzymes studied [1].

In vivo: Pharmacokinetic studies in rats showed that compound CFM 1571 exhibits modest oral bioavailability (12%). Furthermore 32 has an excellent selectivity profile notably showing no significant inhibition of phosphodiesterases or nitric oxide synthases [1].

Clinical trial: Up to now, CFM 1571 is still in the preclinical development stage.

Reference:
[1] Selwood DL, Brummell DG, Budworth J, Burtin GE, Campbell RO, Chana SS, Charles IG, Fernandez PA, Glen RC, Goggin MC, Hobbs AJ, Kling MR, Liu Q, Madge DJ, Meillerais S, Powell KL, Reynolds K, Spacey GD, Stables JN, Tatlock MA, Wheeler KA, Wishart G, Woo CK.  Synthesis and biological evaluation of novel pyrazoles and indazoles as activators of the nitric oxide receptor, soluble guanylate cyclase. J Med Chem. 2001 Jan 4;44(1):78-93.

Featured Products
New Products
 

References on CFM 1571 hydrochloride

NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential.[Pubmed:16955067]

Nat Rev Drug Discov. 2006 Sep;5(9):755-68.

Soluble guanylate cyclase (sGC) is a key signal-transduction enzyme activated by nitric oxide (NO). Impaired bioavailability and/or responsiveness to endogenous NO has been implicated in the pathogenesis of cardiovascular and other diseases. Current therapies that involve the use of organic nitrates and other NO donors have limitations, including non-specific interactions of NO with various biomolecules, lack of response and the development of tolerance following prolonged administration. Compounds that activate sGC in an NO-independent manner might therefore provide considerable therapeutic advantages. Here we review the discovery, biochemistry, pharmacology and clinical potential of haem-dependent sGC stimulators (including YC-1, BAY 41-2272, BAY 41-8543, CFM-1571 and A-350619) and haem-independent sGC activators (including BAY 58-2667 and HMR-1766).

Synthesis and biological evaluation of novel pyrazoles and indazoles as activators of the nitric oxide receptor, soluble guanylate cyclase.[Pubmed:11141091]

J Med Chem. 2001 Jan 4;44(1):78-93.

Database searching and compound screening identified 1-benzyl-3-(3-dimethylaminopropyloxy)indazole (benzydamine, 3) as a potent activator of the nitric oxide receptor, soluble guanylate cyclase. A comprehensive structure-activity relationship study surrounding 3 clearly showed that the indazole C-3 dimethylaminopropyloxy substituent was critical for enzyme activity. However replacement of the indazole ring of 3 by appropriately substituted pyrazoles maintained enzyme activity. Compounds were evaluated for inhibition of platelet aggregation and showed a general lipophilicity requirement. Aryl-substituted pyrazoles 32, 34, and 43 demonstrated potent activation of soluble guanylate cyclase and potent inhibition of platelet aggregation. Pharmacokinetic studies in rats showed that compound 32 exhibits modest oral bioavailability (12%). Furthermore 32 has an excellent selectivity profile notably showing no significant inhibition of phosphodiesterases or nitric oxide synthases.

Description

Soluble guanylyl cyclase (sGC) activator

Keywords:

CFM 1571 hydrochloride,1215548-30-3,Natural Products,Guanylyl Cyclase, buy CFM 1571 hydrochloride , CFM 1571 hydrochloride supplier , purchase CFM 1571 hydrochloride , CFM 1571 hydrochloride cost , CFM 1571 hydrochloride manufacturer , order CFM 1571 hydrochloride , high purity CFM 1571 hydrochloride

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: